PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of ccLink to Publisher's site
 
Cell Cycle. 2010 December 15; 9(24): 4908–4921.
Published online 2010 December 15. doi:  10.4161/cc.9.24.14199
PMCID: PMC3047814
NIHMSID: NIHMS278749

Proteomic profiling of Myc-associated proteins

Abstract

Mammalian c-Myc is a member of a small family of three closely related transcription factors. The Myc family of proto-oncogenes are among the most potent activators of tumorigenesis and are frequently overexpressed in diverse cancers. c-Myc has an unusually broad array of regulatory functions, which include, in addition to roles in the cell cycle and apoptosis, effects on a variety of metabolic functions, cell differentiation, senescence and stem cell maintenance. A significant number of c-Myc interacting proteins have already been defined, but it is widely believed that the c-Myc interactome is vastly larger than currently documented. In addition to interactions with components of the transcription machinery, transcription independent nuclear interactions with the DNA replication and RNA processing pathways have been reported. Cytoplasmic roles of c-Myc have also been recently substantiated. Recent advances in proteomics have opened new possibilities for the isolation of protein complexes under native conditions and confidently identifying the components using ultrasensitive, high mass accuracy and high resolution mass spectrometry techniques. In this communication we report a new tandem affinity purification (TAP) c-Myc interaction screen that employed new cell lines with near-physiological levels of c-Myc expression with multi-dimensional protein identification techniques (MudPIT) for the detection and quantification of proteins. Both label-free and the recently developed stable isotope labeling with amino acids in cell culture (SILAC) methodologies were used. Combined data from multiple biological replicates provided a dataset of 418 non-redundant proteins, 389 of which are putative novel interactors. This new information should significantly advance our understanding of this interesting and important master regulator.

Key words: c-Myc, proto-oncogene, proteomics, tandem affinity purification, MudPIT analysis, SILAC, protein-protein interaction, protein complex

Introduction

c-Myc is a member of a small family of three closely related transcription factors, c-Myc, N-Myc and L-Myc.1 Numerous studies have documented that the Myc family of proto-oncogenes are among the most potent activators of tumorigenesis, and are frequently overexpressed in diverse cancers.2 Deregulation of Myc activity can occur by a range of mechanisms, including indirect ones such as activation of upstream signaling or impairment of its turnover.3 Given that our understanding of these mechanisms remains incomplete, the contribution of Myc to the total load of human cancers is probably still underestimated.

The c-Myc protein is comprised of an N-terminal transcription regulatory domain (NTD), a central region containing PEST degradation and nuclear localization signals (NLS), and a C-terminal DNA binding domain (CTD). The NTD engages in a variety of protein-protein interactions with components of the transcriptional and chromatin remodeling machineries.4 It contains short sequence motifs (MbI and MbII) that are evolutionarily conserved among all Myc family members and are required for biological activity.5 The CTD of c-Myc contains basic, helix-loop-helix and leucine zipper (bHLH-LZ) motifs that mediate interaction with its binding partner Max and the sequence-specific DNA binding of the Myc/Max heterodimer.

Beginning with the identification of Max some twenty years ago, a large number of c-Myc interacting proteins have been defined. The general picture that has emerged is that c-Myc activates its targets by a combination of three mechanisms:6 (1) recruitment of histone acetyl transferase (HAT) activity; (2) recruitment of ATP-dependent SWI/SNF chromatin remodeling complexes; and (3) facilitation of promoter clearance and elongation by an already engaged RNA polymerase II (RNA Pol II). c-Myc is also involved in the repression of many genes, which is mediated by protein-protein interactions and interference with a number of transcription factors, including Miz-1, TFII-I, YY-1, NF-Y and Sp1, or by recruitment of Dnmt3a DNA methyltransferase to specific promoters.7

c-Myc also engages in a number of transcription independent interactions, for example with components of TFII-H to promote mRNA cap methylation,5 with several members of the S phase prereplicative complex to stimulate DNA replication,5 with a number of tumor suppressors and cell cycle regulators that negatively regulate its activity,1 and with multiple ubiquitin ligases to promote either its own destruction or activation of transcriptional activity.3

The currently annotated number of c-Myc interactors in the Human Protein Reference Database (HPRD) stands at seventy one.8 Due to the very low abundance of c-Myc in normal, non-cancerous cells, as well as its rapid turnover most studies have taken advantage of ectopic overexpression or two-hybrid approaches to identify c-Myc binding proteins. Recent advances in proteomics have opened new possibilities for the isolation of complexes under native conditions with confident identification and quantification of the components using ultrasensitive mass spectrometry (MS) techniques. The use of a mass spectrometer with high resolution and high mass accuracy in this study greatly increases the confidence of assignments of interacting proteins and facilitates quantitative analysis using both label free and stable isotope labeling strategies. The only report to date to analyze c-Myc complexes using tandem affinity purification (TAP) combined with the multi-dimensional protein identification technique (MudPIT), identified 220 interacting proteins using an LTQ mass spectrometer.9 The fact that only nine of these proteins overlap with the HPRD annotated interactors underscores the need for further investigations. In this communication we report a new TAP-Myc interaction screen that used new cell lines with near-physiological levels of c-Myc expression as well as the recently developed and quantitative stable isotope labeling with amino acids in cell culture (SILAC) methodology, combined with high mass accuracy and high resolution MudPIT tandem MS/MS spectra detection of proteins on the Thermo hybrid linear ion trap fourier transform ion cyclotron resonance (LTQ-FTICR) mass spectrometer.

Results

Construction of TAP-Myc fusion proteins and testing their in vivo activity.

The TAP-tag was fused to the full length c-Myc protein either at its N-terminus (TAPMyc) or C-terminus (MycTAP; Materials and Methods; Fig. 1A). Since heterologous protein fusions can lead to impairment of biological activity, the TAP-tagged c-Myc proteins were expressed in cells lacking endogenous c-myc and tested for complementation. We have previously constructed by gene targeting c-myc-/- derivatives of the Rat-1 fibroblast cell line;16 these cells display profound proliferation and cell cycle defects,24,25 which can be fully restored by expression of wild-type c-myc cDNA. Stable expression of either TAPMyc or MycTAP in c-myc-/- cells restored normal growth phenotypes (not shown), indicating that the TAP-tag does not affect the biological activity of c-Myc. Examination of extracts prepared from the complemented cell lines by immunoblotting showed that the TAP-tag fusion proteins remained intact (not shown); complementation was thus not due to release of c-Myc from the fusion proteins by proteolysis. TAPMyc and MycTAP were also expressed in human fibroblasts transformed with telomerase and SV40 large and small T antigens (LF1/TERT/LT/ST).11 Ectopic expression of biologically active c-Myc significantly accelerates the growth of LF1/TERT/LT/ST cells, and endows them with the ability to grow in an anchorage-independent manner.11 In this biological assay TAPMyc and MycTAP also displayed full c-Myc activity (not shown).

Figure 1
Size exclusion chromatography of nuclear TAPMyc complexes. (A) Schematic representation of the TAPMyc protein. Structure of the TAP-tag: Prot A, protein A; TEV, TEV protease cleavage site; CBP, calmodulin binding protein. c-Myc contains a N-terminal transactivation ...

Extraction of high molecular weight TAP-Myc complexes.

LF1/TERT/LT/ST cells maintain stable expression of ectopic c-Myc because it confers a proliferative advantage. We initially worked with both TAPMyc- and MycTAP-expressing LF1/TERT/LT/ST, but for the large scale purifications used TAPMyc cells simply because they gave slightly higher yields during extraction. HAMyc-expressing cells were used as negative controls: they express HAMyc at levels equivalent to TAPMyc or MycTAP cells and display identical growth properties, but the HA-tag does not bind to IgG or calmodulin beads.

Two different lysis conditions were tested for the extraction of nuclear c-Myc complexes: the classical Dignam et al. method18 frequently used for the purification of transcription factors, and the Evan and Hancock method,17 developed specifically for the extraction of c-Myc. Both of the methods employ hypotonic buffer lysis to remove the cytoplasm; to extract the nuclei the Dignam et al. method uses high salt and glycerol, while the Evan and Hancock method uses physiological salt concentrations in the presence of a non-ionic detergent. Both methods resulted in the extraction of 50–70% of total TAPMyc, MycTAP or HAMyc; the remainder was associated with the insoluble nuclear pellet and could only be extracted by complete solubilization with SDS. Digestion of chromosomal DNA with DNaseI during the extraction did not recover any additional TAPMyc, MycTAP or HAMyc. Eventually the Evan and Hancock method was adopted for large scale purification, simply because it required fewer steps and gave a slightly higher yield than the Dignam et al. method.

As an initial characterization, nuclear extracts were subjected to size exclusion chromatography by FPLC on a Superdex 200 column, and the fractions were immunoblotted for either the TAP-tag or Max. The great majority of TAPMyc or MycTAP was found to be present in megadalton molecular weight complexes (Fig. 1B). A minor peak was seen in the 200–300 kDa range, and essentially no signal was seen in the region of monomeric Myc or Myc/Max dimers. Max comigrated with Myc in the high molecular weight region. The large TAPMyc and MycTAP complexes migrated in the first few included fractions just behind the void volume; given the low resolution of gel filtration in this range, multiple different complexes could be present and comigrating. The migration of the complexes was not influenced by binding to DNA because the elution behavior did not change when extracts were treated with DNaseI (not shown). Likewise, the high molecular weight migration was not due to the presence of protein-detergent micelles, since extracts prepared using the Dignam et al. method (which does not employ any detergent) resulted in identical column profiles. Finally, the migration was not influenced by the TAP-tag, because HAMyc behaved in the same manner.

Tandem affinity purification.

This purification scheme involved a pull-down on IgG Sepharose beads, release by cleavage with TEV protease, a second pull-down on Calmodulin Sepharose beads and release by the chelation of calcium (see Fig. 2A for a schematic and Materials and Methods for details). Myc and Max proteins were monitored throughout the purification by immunoblotting (Fig. 2B). Both Myc and Max were detected in the final EGTA eluted fractions and were maintained at the same relative ratio as in the starting material, indicating that Myc complexes, at least with respect to Myc/Max dimers, remained intact during the purification. The purification of TAPMyc was specific, since HAMyc showed no interaction with either the IgG beads or the calmodulin beads and Max was never detected at any of the purification steps when HAMyc-containing extracts were processed.

Figure 2
Tandem affinity purification of TAPMyc complexes. (A) For single-step purifications, after washing IgG beads with buffer B, beads were washed with buffer B without protease and phosphatase inhibitors, casein and NP40, and bound proteins were eluted with ...

The Myc complexes were further characterized using a series of ultracentrifugation steps (Fig. 3A). A small portion of the Calmodulin Sepharose eluate was in the form of aggregates, as evidenced by the fact that 10–15% of total Myc and Max could be pelleted by short (20 min) 25,000 g and 50,000 g spins. After this initial clearing, very little Myc and Max was pelleted by subsequent 75,000 g and 100,000 g spins. That high molecular weight complexes were present was indicated by the observation that longer (2 hr) centrifugation at 100,000 g could pellet over 50% of the Myc and Max present. The presence of complexes was further demonstrated by concentrating the Calmodulin Sepharose eluate by centrifugal ultrafiltration (using a 10 kDa cutoff Microcon membrane) and Superdex 200 size exclusion FPLC (Fig. 3B) under the same conditions used previously to characterize the crude nuclear extracts. As before, Myc and Max were present predominantly in megadalton complexes that migrated in the first few included fractions.

Figure 3
Characterization of TAPMyc purified complexes. (A) The Calmodulin Sepharose eluate was subjected to a series of spins: spin 1, 25,000 g, 20 min, spin 2, 50,000 g, 20 min, spin 3, 75,000 g, 20 min., spin 4, 100,000 g, 20 min. The pellet of each spin was ...

Following concentration, the Calmodulin Sepharose eluate was also analyzed by SDS-PAGE and silver staining. A number of proteins were found to be present (Fig. 4), but the majority of them are likely to be nonspecific since they were found in purifications starting with either TAPMyc or HAMyc containing extracts. The migration positions of Myc and Max were ascertained by immunoblotting a gel loaded with the same samples. The most prominent specifically enriched band visible by silver staining was Myc itself. Max was obscured by IgG and casein bands migrating in the lower portion of the gel. Despite extensive washing during purification, some IgG chains and casein remained present in the final fractions. Several TAPMyc-enriched bands were visible, but none stained as intensely as Myc.

Figure 4
SDS-PAGE and silver stain analysis of purified TAPMyc complexes. The Calmodulin Sepharose eluate was concentrated by centrifugal ultrafiltration (Microcon, Millipore) and 3 µg protein was run on a 3–10% polyacrylamide gel followed by silver ...

MS/MS analysis of the TAP samples.

The Calmodulin Sepharose eluate was finally processed for MS using MudPIT (Materials and Methods). Tryptic digests were resolved over a strong cation exchange column followed by a reverse phase column for the first and second dimensions, respectively, injected online into a Thermo Finnigan LTQFT hybrid ion trap fourier transform mass spectrometer, and tandem MS/MS spectra were acquired in real time. This approach resulted in the detection of 1,645 proteins, of which 48 were enriched > two-fold in the TAPMyc sample and identified with 2 or more unique peptides (Table 1, see Sup. Table 2 for summary of all experiments). Max was detected with 7 peptides. The great majority of proteins (1,469) were identified with a single peptide only.

Table 1
Summary of the two-step purification experiment

The limited number of multipeptide hits was likely due to the small amount of material present in the final Calmodulin Sepharose eluate. The TAP-tag and associated purification scheme employed here can be limited by serious inefficiencies and losses of material at several steps (www.proteomecenter.org/protocols/), which we were unable to overcome in spite of extensive optimization. Likewise, it was not possible to increase the amount of starting material (~13 mg of nuclear extract) which could be recovered from −3 × 108 cells grown on 32 15 cm plates (since we always grew and processed TAPMyc and HAMyc cells in parallel, one experiment involved the harvesting of 64 15 cm plates). We estimated that TAPMyc was present at ~0.001% of total protein in the nuclear extract, and at ~2% in the ~3 µg of the final Calmodulin Sepharose eluate, for an enrichment of some 1,000–2,000-fold. We attempted to adapt the TAPMyc expressing cell lines to growth in liquid suspension but did not succeed. We also found that freezing at any point during the purification (including the cell pellets) resulted in the disruption of the interaction between Myc and Max, and hence the entire procedure, from cell harvest to elution from the Calmodulin Sepharose, had to be performed in a single run of some 36 hrs.

Single step purification and MS/MS analysis.

To overcome these problems and scale up the amount of protein needed for MS/MS analysis we eliminated the second affinity step (Calmodulin Sepharose) of the purification, and simply eluted TAPMyc complexes from the IgG Sepharose beads with low pH. This single step purification greatly reduced the time line and increased the yields, however, it also significantly reduced the enrichment. Our rationale was that without this sacrifice we could not obtain adequate amounts of material for MS/MS, and that MudPIT had the ability to resolve the much more complex protein mixtures. To increase the confidence of this approach, we performed four complete biological replicates (cells grown on separate occasions and processed independently all the way through MS/MS analysis). Because of the complexity these data are presented as supplemental online information (Sup. Table 1, also see Sup. Table 2 for summary of all experiments). Myc and Max were enriched in all the replicates. Combined between all four replicates, this approach resulted in the detection of 5,603 proteins. 3,832 were identified with a single peptide only, and 320 were specifically enriched in the TAPMyc sample.

SILAC, single step purification and MS/MS analysis.

To decrease the technical variability between replicate analyses, we obtained quantitative MS data using SILAC, which allows experimental and reference cells to be mixed, processed and analyzed as a single combined sample. Cultures were grown for at least six generations in “heavy” medium (Invitrogen) supplemented with dialyzed serum, [U-13C6]-L-lysine and [U-13C6]-L-arginine. Control cultures were grown under identical conditions except that “light” lysine and arginine were used for supplementation. Cells grown in light and heavy media were mixed in equal proportions prior to the preparation of extracts to ensure that all biochemical procedures were applied equivalently to both (Fig. 5). Extracts were subjected to the one step purification, MudPIT and MS/MS analysis as described above. Four independent biological replicates were performed. In three experiments HAMyc cells were grown in heavy media and TAPMyc cells in light media; in the fourth the label was switched. The combined data from all replicates resulted in the detection of 722 proteins. 212 were identified with a single peptide only, and 87 were specifically enriched in the TAPMyc sample (Table 2; also see Sup. Table 2 for summary of all experiments). As in the label-free experiments, Myc and Max were detected with multiple peptides in all experiments and were specifically enriched only in TAPMyc samples.

Figure 5
Single-step purification of TAPMyc complexes. TAPMyc and HAMyc cells, grown in light and heavy media respectively, were pooled in equal proportions and subjected to the Evan and Hancock nuclear extraction. Samples were analyzed by immunoblotting; the ...
Table 2
Summary of the one-step purification SILAC experiments1

Discussion

We employed three distinct experimental approaches for the purification and identification of c-Myc complexes. All were based on the ectopic expression of a TAPMyc fusion protein in a human fibroblast cell line. We verified that the TAPMyc fusion protein we constructed was biologically active and that it conferred the expected phenotype in the cell line used for purification. Our first approach (designated two-step) employed tandem affinity purification on IgG beads followed by Calmodulin beads. In the second approach (designated label-free) we performed only one round of purification using IgG beads. In the third approach (designated SILAC) we added metabolic labeling with 13C lysine and arginine prior to the single-step purification on IgG beads. Four independent biological replicates were performed in both the label-free and SILAC series of experiments. All purifications were processed using MudPIT followed by MS/MS analysis.

We found 48 proteins to be specifically enriched in the two-step experiment (Table 1; also see Materials and Methods for definitions of enrichment), 320 proteins in the label-free experiments (Sup. Table 1) and 87 proteins in the SILAC experiments (Table 2). Removing Myc from these lists provides 418 non-redundant proteins as the combined total of putative c-Myc interactors identified in this study (Sup. Table 3). Our combined dataset of 418 proteins shares 27 proteins with the 220 protein dataset of Koch et al.9 (12% overlap) and six proteins with the 71 protein HPRD dataset of known c-Myc interactors.8 (8% overlap; Sup. Table 3). The overlaps between our three experimental datasets range from 8% to 29% (Fig. 6) with 5 proteins being common to all three datasets. Two (40%) of these proteins (MAX, TUBA4A) are found in both the HPRD and Koch et al. datasets. Three proteins (ERBB2IP, PRKCDBP, UBC) are novel interactors. Twenty-four additional proteins are shared by two datasets (Fig. 6 and Sup. Table 3), and among these are twenty novel interactors. Another useful way to evaluate the data is to consider the proteins that scored consistently in the biological replicates: 33 interactors were present in at least three out of four biological replicates in the label-free experiments (Sup. Table 1), and 31 proteins scored in that category in the SILAC experiments (Table 2). Of the 29 interactors shared between two (or more) experimental approaches, 14 (50%) were present in three (or more) biological replicates in the label-free or SILAC experiments, indicating that these top scoring hits are being repeatedly and consistently identified.

Figure 6
Venn diagram of the relationships between the two-step, label-free and SILAC series of experiments. The overlap between the two-step and label-free datasets is 9 proteins (19% of two-step), between the two-step and SILAC datasets 7 proteins (15% of two-step), ...

Of the novel proteins present in all three experimental approaches, UBC encodes one of the polyubiquitin proteins encoded by the human genome. Rather than an interactor, it is likely that ubiquitin was identified by virtue of its covalent modification of a subset of c-Myc proteins. The ability to repeatedly obtain a signal from this small and transient pool of c-Myc molecules underscores the sensitivity of our methodologies. PSMD2 (a 26S proteasome regulatory subunit) was present among the proteins shared between two experimental approaches, and PSMA3 (a proteasomal subunit) and RNF130 (a E3 ubiquitin ligase) were identified in three out of four label-free and SILAC biological replicates, respectively. Koch et al.9 also identified a significant number of components in the proteasomal pathways, suggesting that TAP-tagged Myc proteins, like native c-Myc, are being targeted for degradation.

Of the remaining two novel interactors present in all three experimental approaches, ERBB2IP, also known as Erbin, is a protein containing 17 leucine-rich repeats and one PDZ domain that was identified as an interactor and regulator of the receptor tyrosine kinase ErbB2/Her2.26 Subsequently it was shown to affect the Ras signaling pathway by disrupting Ras-Raf interaction,27 and of relevance to c-Myc, interacting though its PDZ domain with several transcriptional regulators including β-catenin, c-Rel, Smad3 and HTLV-1 Tax.2830 Little is known about the second novel interactor, PRKCDBP. This protein, also known as SRBC, was identified as a protein kinase C (PKC) δ binding protein and in vitro substrate that contains a leucine zipper-like motif and two PEST sequences.31 The most abundant literature on SRBC implicates it as a tumor suppressor gene frequently methylated in a variety of human cancers.3236 Recently, SRBC was identified as a caveolin-1 adapter molecule.37 Interestingly, SRBC was represented by multiple peptides in all four SILAC biological replicates, and PTRF, a protein related to SRBC and likewise a caveolin-1 adapter, was present in two of our three experimental approaches as a c-Myc interactor (Sup. Table 3). It is tempting to speculate that intracellular trafficking mediated by caveolae membranes is involved in regulating c-Myc activity; along similar lines, caveolin-1 was recently implicated in activating p53.38

Of the 29 c-Myc interactors identified in two (or more) of our three experimental approaches (Sup. Table 3), 8 (28%) are cytoskeletal proteins. Three major categories of filamentous proteins were present: actins, lamins and tubulins. Multiple tubulins are documented as c-Myc interactors in HPRD, and association with lamin A (LMNA) and beta actin (ACTB) has been reported in the literature.9,39 We found TUBA4A in all three of our experimental approaches, and LMNA and ACTC1 in two. LMNA and ACTG1 were present in three SILAC biological replicates, and TUBB6 in three replicates of the label-free experiments. In addition, numerous cytoskeleton associated proteins, such as filamin (FLNA), microtubule associated proteins (CEP55, CEP170, MAP1A) and others were identified. LMNA is known to functionally interact with several transcription factors and chromatin associated proteins,40 and many of the other identified proteins have nuclear as well as cytoplasmic localizations and roles. However, a number of reports over the years have implied cytoplasmic roles for the c-Myc protein, and recently a calpain protease generated fragment of c-Myc, Myc-Nick, has been identified as a microtubule-binding protein involved in promoting tubulin acetylation and cytoplasmic reorganization.41 In light of this discovery, our finding of several endoplasmic reticulum and vessicle-associated proteins, including several RAB GTPases involved in intracellular vessicular transport, is of heightened interest.

Not surprisingly, a major category of c-Myc interactors were transcription factors and chromatin-associated proteins, including ADNP, CDYL, ETV3, FOXP1, NONO, PTRF, RUNX1, TCF12, YBX1 (7 of 29 or 24%, identified in two or more of our experimental approaches, Sup. Table 3). Of the novel interactors identified here, RUNX1 (also known as Acute Myeloid Leukemia 1 Oncogene, AML1), is important in coordinating the expression of numerous cell cycle regulators. RUNX1 interacts with several transcription cofactors, including the histone acetylase p300 (EP300) and the CREB-binding protein (CREBBP, also known as CBP), both of which have also been reported to interact with c-Myc.42,43 Furthermore, the RUNX1 regulatory subunit CBFB was identified in two of our experimental approaches, making this an interesting topic for further studies.

We also performed a Gene Ontology (GOstat) analysis44 on the entire list of 418 non-redundant proteins identified in this study (Sup. Tables 46). In the Cellular Compartment ontology (Sup. Table 4) nucleus was most highly enriched, but was followed closely by the cytoplasm, and interestingly, the mitochondrion (the preparation of nuclei we used, namely gentle lysis of cytoplasmic membranes with NP40, only provides an enrichment, and hence some cytoplasmic components were present in the extracts used for purification). Both the microtubule cytoskeleton and actin cytoskeleton were significantly enriched. A variety of cytoplasmic vesicles were also enriched. In the Biological Process ontology (Sup. Table 5), transcription was the most highly enriched, followed by the cell cycle. Also highly enriched were DNA processes such as replication, repair and chromatin modification, followed by cytoskeletal processes such as cellular trafficking and localization, and cell stress and death responses including apoptosis. In the Molecular Function ontology (Sup. Table 6), the most highly enriched categories were nucleotide/ATP binding. Also highly enriched were nucleic acid/RNA/DNA binding, transcription factor biding and a variety of transcription associated activities. Cytoskeletal protein binding, helicase activity and a variety of metabolic activities were also significantly enriched. This analysis is highly consistent with c-Myc being predominantly a nuclear protein that interacts with numerous proteins involved with transcription and chromatin organization. The strong enrichment for cell cycle and apoptosis is consistent with those known functions of c-Myc. The interaction with the cytoskeleton is also prominent and recently supported by direct experimental evidence.41 Not documented to date but of note are the enrichments for the mitochondrion and cytoplasmic vessicles, the latter of which may be relevant to the interaction of c-Myc with PRKCDBP (SRBC, above), a component of caveolae. We also performed an enrichment analysis for interacting protein domains,45 in which the PDZ domain was the top hit (Sup. Table 7). Interaction of c-Myc with PDZ domains has not been previously noted, and may be relevant for its interaction with ERBB2IP (above), a candidate found in all three of our experimental approaches.

Considering our most highly purified c-Myc complexes (two-step purification, Fig. 4) it is interesting to note that no interacting protein, other than Max, was as abundant as c-Myc (in Fig. 4 Max is obscured by the contaminating IgG light chains, but immunoblotting experiments indicate that it co-purifies with c-Myc in roughly stoichiometric amounts). Koch et al.9 observed a similar lack of equivalently staining bands in two separate purifications. Taken together, these data suggest that c-Myc is not found predominantly in a single, multi-component complex, such as, for example, the SAGA complex,46 components of which have been shown to interact with c-Myc.6 The patterns of purification observed by us and Koch et al.9 are more consistent with c-Myc molecules being dispersed among multiple macromolecular complexes. A corollary of this interpretation, also consistent with the very low expression levels of c-Myc, is that the macromolecular complexes that interact with c-Myc contain the protein in very small amounts.

Size exclusion chromatography (Figs. 1 and and33) also indicated that c-Myc is found predominantly in large (>1 mDa) macromolecular complexes. The resolution of this method in this size range is not adequate to determine the number of distinct complexes that may be present. A minor peak was seen in the 200–300 kDa range, and essentially no signal was seen in the region of Myc/Max dimers. Max co-migrated with Myc under all conditions. Koch et al.9 used sucrose gradient sedimentation, and reported c-Myc in a large number of protein complexes with a broad range of molecular weights. They also observed c-Myc in a size range consistent with Myc/Max dimers. The latter discrepancy could be due to several factors. First, we prepared nuclear extracts whereas Koch et al. used whole cell extracts. Second, the levels of c-Myc overexpression were likely higher in the cell lines used by Koch et al. Third, the presence in c-Myc complexes of fibrous proteins with extended conformations, such as actin, tubulin or lamin, could anomalously affect our gel filtration elution profiles. Finally, Koch et al. used three cycles of freeze-thawing to promote the lysis of cells, whereas we observed that any freezing-thawing (of either cell pellets or extracts) caused considerable disruption of complexes in our hands. More importantly, however, both studies documented the presence of significant amounts of very large Myc-containing complexes that were relatively stable during the TAP procedure.

Given the involvement of c-Myc in diverse biological processes, and the several already reported interactions with large, multicomponent protein complexes, it is widely believed that the c-Myc interactome is vastly larger than currently documented. Only one prior report has used an unbiased, genome-wide proteomic approach for the identification of c-Myc-interacting proteins.9 Given the importance of c-Myc in human cancer, the paucity of such efforts reflect the biochemical challenges in working with c-Myc: its low abundance in the cell, its highly unstable nature, and its many interacting partners. The main advances of the study reported here are the use of high resolution, high mass accuracy LC/MS methods for the detection of peptides from c-Myc interacting proteins, and the application of SILAC labeling of proteins in vivo. To our knowledge this is the first study to employ SILAC to obtain quantitative data of the c-Myc interactome coupled with a stringent cut-off of 2% false discovery rate (FDR) for the identification of interacting proteins estimated by a decoy database search. The datasets presented here are highly consistent with prior studies, and greatly expand our knowledge of c-Myc interacting protein partners. This new information should significantly advance our understanding of this interesting and important master regulator.

Materials and Methods

Construction of Myc-Tap fusion proteins.

Mouse c-myc cDNA was PCR amplified with primers containing restriction sites for subsequent subcloning: ACT GAG TGA TCA CTA GGA AGA TCT CAT CCG GAA TTC ACC ATG CCC CTC AAC GTG AAC (forward) and GCT CCG CTC GAG GGC GTA CAA TTG TCG GCG TTA GGA TCC AGA GGT TTC GAA GCT GTT C (reverse; restriction sites underlined). To allow the introduction of a C-terminal TAP-tag the stop codon of c-myc was replaced with a BamHI site. This also changed the last amino acid of c-Myc from alanine to serine, which has previously been shown not to affect c-Myc activity.10 The amplified fragment was digested with BclI and XhoI and placed into the pWZL-Blast retroviral vector11 digested with BamHI and SalI. N- and C-terminal TAP-tag vectors, pZome1-N and pZome1-C,12 were obtained from EUROSCARF (http://web.uni-frankfurt.de/fb15/mikro/euroscarf). The TAP-tags were released from the pZome vectors using BamHI and EcoRI. To create the N- or C-terminal TAP-Myc fusion, the corresponding TAP-tag was ligated into the pWZL-Blast-Myc plasmid digested with BglII and EcoRI (for N-terminal fusion) or with BamHI and MfeI (for C-terminal fusion). The plasmids are referred as pWZL-Blast-TAPMyc for the N-terminal fusion and pWZL-Blast-MycTAP for the C-terminal fusion.

Cell lines and culture conditions.

LF1/TERT/LT/ST cells were derived from LF1,13 normal human diploid fibroblasts (HDF) by sequential introduction of human telomerase and simian virus 40 large T and small T antigens using retroviral vectors.11 Retrovirus vectors were packaged using the amphotropic Phoenix cell line obtained from G. Nolan (Stanford University) according to their recommended protocol (http://www.stanford.edu/group/nolan). LF1/TERT/LT/ST cells were infected with pWZL-Blast-TAPMyc and pWZL-Blast-MycTAP (this communication) and with pWZL-Blast-HAMyc11 and selected with three µg/ml of blasticidin. A second round of selection for vigorous anchorage independent growth was imposed by plating pools of drug resistant cells in soft agar,14 and clonal cell lines were established from large colonies. The resultant cell lines, all derivatives of LF1/TERT/LT/ST, are referred to as TAPMyc, MycTAP and HAMyc. TGR-1 is a hprt- subclone of the Rat-1 cell line.15 Homozygous knockout c-myc-/- cells were generated by gene targeting from the TGR-1 cell line,16 and a subclone designated HO15.19 was used for further experiments.

All HDF-derived cell lines were initially grown in Ham's F-10 medium supplemented with 15% fetal bovine serum in an atmosphere of 92.5% N2, 5% CO2 and 2.5% O2. For large scale biochemical experiments TAPMyc, MycTAP and HAMyc cells were later adapted to growth in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% cosmic serum (Hyclone). These, and all subsequent cell lines were cultured in air adjusted to 5% total CO2 content. Rat-1 derivatives were grown in DMEM supplemented with 10% calf serum. Phoenix cells were grown in DMEM supplemented with 10% heat-inactivated fetal bovine serum. All cultures were at 37°C. All media were supplemented with glutamine, penicillin and streptomycin. SILAC was performed as specified by the manufacturer (Invitrogen). Cultures were grown in SILAC medium using the Invitrogen MS10030 kit for at least six population doublings. The heavy amino acids used for the labeling were [U-13C6]-L-lysine (provided in the SILAC medium kit) and [U-13C6]-L-arginine (Invitrogen, MS10011).

Preparation of nuclear extracts.

Cells were grown in 15 cm dishes to 90% confluency, washed three times with ice cold phosphate buffered saline (PBS), and harvested by scraping into PBS on ice. A typical experiment used 35 plates, which yielded 4–5 ml of packed cell volume (PCV), or 1.5 × 108 to 2 × 108 cells. An aliquot of ~106 cells was removed for immunoblotting. The remaining cells were centrifuged at 1,000 rpm for 5 min at 4°C and immediately processed for lysis and extraction. In SILAC experiments cells grown in heavy and light media were scraped in PBS as above, equal PCV of each were combined prior to lysis and extraction, and henceforth treated as a single sample. The PCV were verified to contain equivalent amounts of protein. Two lysis and extraction protocols were used (with minor modifications): Evan and Hancock (1985),17 and Dignam et al. (1983).18 In the Evan and Hancock protocol, cells were gently resuspended in three PCV of low salt buffer (100 mM HEPES pH 6.8, 5 mM KCl, 5 mM MgCl2 and 0.5% NP40, supplemented with protease and phosphatase inhibitors (1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 mM PMSF, 10 mM β-glycerophosphate, 2 mM sodium orthovanadate) and incubated on ice for 10 min. Nuclei were pelleted by centrifugation as above (1,000 rpm for 5 min at 4°C), and the supernatant was saved as the cytoplasmic fraction. Nuclei were washed once in one PCV of low salt buffer, pelleted, and the supernatant was saved as the cytosolic wash. To lyse the nuclei, the pellet was resuspended in two PCV of high salt buffer (100 mM HEPES pH 6.8, 250 mM NaCl, 5 mM KCl, 5 mM MgCl2 and 0.5% NP40, supplemented with protease and phosphatase inhibitors) and incubated on ice for 30 min with occasional homogenizing using a syringe with a 25 gauge needle. The lysate was centrifuged as above, the supernatant was collected as the nuclear extract, and the residual insoluble material as the nuclear pellet. The nuclear extract was further centrifuged at 16,300 x g for 30 min at 4°C to remove aggregated proteins. At each step of the protocol a fraction equivalent of 106 starting cells was removed to monitor the efficiency of the extraction by immunoblotting. Extraction in the presence of DNase was performed as above except that 1 µl (2 units) of DNaseI (New England Biolabs, M0303) was added per 50 µl of high salt buffer. The extracts were used immediately for subsequent steps, since freezing and thawing resulted in some dissociation of Myc-Max complexes.

The steps of the Dignam et al. protocol were similar to those of the Evan and Hancock protocol with the exception of the buffer composition. Low salt buffer: 10 mM Tris pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.5 mM DTT and 0.2 mM PMSF; high salt buffer: 20 mM Tris pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF. After the high speed centrifugation to remove aggregates, the nuclear extract was dialyzed using a 10 kDa cut-off membrane against 20 mM Tris pH 7.9, 10% glycerol, 0.1 mM KCl, 0.2 mM EDTA, 10 mM β-mercaptoethanol and 0.2 mM PMSF, for five hours at 4°C with two changes of buffer. Dialyzed nuclear extract was further cleared by centrifugation at 16,300 x g for 30 min at 4°C and immediately used for subsequent steps.

Size exclusion chromatography.

Size exclusion chromatography was performed using a Superdex 200 column (Amersham Biosciences). Nuclear extracts prepared using the Evan and Hancock protocol were adjusted to 150 mM NaCl by dilution with 20 mM HEPES pH 6.8. The column buffer was 20 mM HEPES pH 6.8, 150 mM NaCl, 1 mM DTT, 0.5 mM EDTA and 0.1% NP40. For extracts prepared with the Dignam et al. protocol the column was equilibrated and run with dialysis buffer. The columns were run at 0.25 ml/min to 0.5 ml/min at 4°C on the GE Health Care/Amersham Biosciences fast protein liquid chromatography (FPLC) system. 250 µl fractions were collected and 90–100 µl of each fraction was analyzed by immunoblotting.

Immunoblotting.

Samples were separated by 10% SDS PAGE, electro transferred to PVDF membrane (Millipore), and processed using standard protocols.19 The primary antibodies were: HA, Covance (MMS-101P); c-Myc, Upstate (06-340); Max, Santa Cruz (sc-197). Horseradish peroxide (HRP)-conjugated secondary antibodies were obtained from Jackson Immuno Research. Chemiluminescence was detected using a kit from Pierce (34080).

TEV protease purification.

A bacterial expression construct of TEV protease was obtained from D. Waugh (National Cancer Institute, Frederick, MD). Cultures of 200 ml were grown at 37°C to an OD600 of 0.7, TEV protease expression was induced with 1 mM IPTG, and incubation was continued overnight at 18°C. Cells were collected by centrifugation and pellets were stored at −80°C. Lysis was performed by sonication using a Branson S-250D digital sonifier equipped with a 0.5 inch tip (4 min total time, 50% amplitude, 2 s on/8 s off cycles) in His-tag lysis buffer (50 mM Tris pH 8.0, 5 mM imidazole, 500 mM NaCl, 0.1% Triton-X 100 and protease inhibitors). The extracts were centrifuged at 40,000 x g for 35 min at 4°C to pellet debris and insoluble proteins. The cleared supernatant was used for TEV protease purification over a Ni-NTA column (Qiagen) using His-tag buffer A (50 mM Tris pH 8.0, 5 mM imidazole and 500 mM NaCl) for binding and washing, and His-tag buffer B (50 mM Tris pH 8.0, 500 mM imidazole and 500 mM NaCl) for elution. Fractions eluted from the Ni-NTA column were analyzed by SDS PAGE to identify the peak fractions of TEV protease, which were then pooled and dialyzed against buffer C (50 mM Tris pH 7.5, 1 mM EDTA and 5 mM DTT). After dialysis, the sample was again cleared by centrifugation, glycerol and Triton-X100 were added to 50% and 0.1% final concentrations, respectively, and aliquots were stored at −80°C.

TAP purification.

IgG sepharose beads (GE Health Care/Amersham Biosciences) were first washed with Evan and Hancock high salt buffer (without protease and phosphatase inhibitors), followed by three rounds of successive washes with low pH buffer (0.1 M NaC2H3O2 pH 4.0 and 0.5 M NaCl) and high pH buffer (0.1 M Tris pH 8.0 and 0.5 M NaCl). The beads were then washed once with high salt buffer, three times with 0.1 M glycine pH 2.5, and twice again with high salt buffer. Finally, the beads were equilibrated in high salt buffer (supplemented with protease and phosphatase inhibitors) and blocked overnight at 4°C using 1 mg/ml casein (Sigma, C6905-1G) in high salt buffer. Blocked IgG beads were incubated with nuclear extract for 2 h at 4°C with gentle rotation (50–60 µl of blocked beads were used per 1 mg of nuclear extract protein, 9–14 mg total protein was processed in a typical large scale purification, and the concentration of the extract was 1 mg/ml). The beads were washed three times with high salt buffer containing 1 mg/ml casein, followed by four washes with TEV protease reaction buffer (10 mM Tris pH 8.0, 150 mM NaCl, 0.1% NP40, 0.5 mM EDTA, 1 mM DTT and 1 mg/ml casein). All the washes were done for 5 min at 4°C with gentle rotation. IgG beads were then incubated with TEV protease in a 200 µl reaction volume per mg of protein overnight at 4°C. At the end of the reaction the beads were pelleted, the supernatant was collected, its volume was measured and CaCl2 was added to 3 mM (final concentration). The beads were washed three times with 1.5 to 2.4 ml (170 µl per 1 mg of input extract protein) of calmodulin binding (CB) buffer (10 mM Tris pH 8.0, 150 mM NaCl, 1 mM Mg-acetate, 1 mM imidazole, 2 mM CaCl2, 0.1% NP40 and 10 mM β-mercaptoethanol), the washes were added to the TEV supernatant, and this pooled fraction was then used for the subsequent calmodulin pulldown. Prior to use, Calmodulin Sepharose (Stratagene 214-303-52) were washed twice in CB buffer and once in CB buffer containing 1 mg/ml casein. 30–35 µl of calmodulin beads were used per 1 mg of starting nuclear extract, and were incubated with the pooled TEV supernatant for 2 hr at 4°C. The calmodulin beads were then washed once with CB buffer containing 1 mg/ ml casein, four times with CB buffer without casein, and twice with CB buffer without casein, NP40 and imidazole. After the final wash the beads were incubated in one bead volume of elution buffer (50 mM NH4HCO3 pH 8.5, 150 mM NaCl and 2 mM EGTA) for 15 min at room temperature. Two rounds of elution were done and combined. The eluted fractions were then analyzed in four ways: (1) estimation of total protein (Coomassie plus kit, Pierce 23236); (2) SDS-PAGE followed by silver staining (Pierce 24612); (3) SDS-PAGE followed by immunoblotting; and (4) mass spectrometry. Small aliquots were removed at each step of the purification and analyzed by immunoblotting for Myc and Max proteins to monitor their partitioning during the purification and to estimate the efficiency of recovery at each step. Concentration of the final EGTA eluted fraction for SDS-PAGE and silver stain analysis was done by centrifugal ultrafiltration (10 kDa cut-off Microcon, Millipore). To minimize protein loss due to sticking to the walls of the Microcon device, the concentrator was pretreated with a 5% solution of Tween-20, as recommended by the manufacturer.

For one-step purification based only on the protein A epitope of the TAP-tag, the pulldown using IgG beads was performed as described above. After incubation with nuclear extract, the beads were washed four times with Evan and Hancock high salt buffer supplemented with protease and phosphatase inhibitors, 1 mg/ml casein and 0.1% NP40, followed by three washes of the same buffer without protease and phosphatase inhibitors, casein and NP40. The bound proteins were eluted from the beads using one bead volume of 100 mM glycine pH 2.5 followed by one bead volume of 100 mM glycine pH 2.3. Each step of the elution was performed for 10 min. at room temperature. Eluted fractions were neutralized by adding 0.1 volumes of 1 M Tris pH 8.5 and pooled for subsequent mass spectrometry analysis.

Mass spectrometry analysis.

Starting sample volume was estimated, solid urea was added to a final concentration of 8 M, and the samples were incubated for 5 min at 95°C. The urea concentration was lowered to 4 M by dilution with 50 mM NH4HCO3 pH 8.5 for EGTA eluted fractions, or with 100 mM NH4HCO3 pH 8.5 for acid eluted fractions (to achieve a final concentration of 50 mM NH4HCO3 pH 8.5). Tryptic digestion was performed using 2.5 µg of trypsin (Promega 14005-858) overnight at 37°C. All these and subsequent steps were performed using 1.5 ml Sarstedt microfuge tubes (Fisher Scientific 50809205). After tryptic digestion the peptides were desalted using C-18 reverse phase columns (Michrom Bioresources, TR1/25109/52). The C-18 column was washed twice with 0.1% acetic acid/water, the peptide sample was brought to pH 3.0 using 1 M HCl, and loaded on the column. The column was washed twice with 0.1% acetic acid, the peptides were eluted with (7:3) acetonitrile: 0.1% acetic acid, and the eluted sample was dried using a speed vacuum apparatus. MudPIT separation20 employed a strong cation exchange (SCX) column for the first dimension separation and a C-18 reverse phase column for the second dimension separation. An in-house SCX column of polysulfoethyl A (300 Å, 5 µm) resin (Nest Group, PBMSE0503) was made in a fused silica capillary of 250 µm inner diameter (Polymicro Technologies 2000026). The resin was resuspended in methanol and loaded into the capillary using a high pressure chamber system “bomb” (http://fields.scripps.edu/mudpit/). The column was packed up to a length of 15–20 cm. After packing, the column was washed using the bomb with water for 30 min. and then with 0.2 M NaH2PO4, 0.3 M CH3COONa for 30 min. The column was then connected to the HPLC system Agilent Series 1100 quaternary pump, and washed with water for 45 min at the flow rate of 0.1 ml/min. To prepare the column, 200 pmol of bovine serum albumin (BSA) tryptic digest was bomb loaded onto the column, which was then washed with 1 M CH3COONa for 45 min. using the bomb. Finally, the column was washed using the HPLC pump as above.

To perform the SCX separation, a dried peptide sample was reconstituted in 0.1% acetic acid/water and loaded onto the column using the bomb. The nonretained fraction was collected to assay for efficiency of peptide binding to the column. The SCX column was then connected to the HPLC system and peptides were eluted using a 12-step salt gradient made by combining buffer A (30% acetonitrile, 5 mM NaH2PO4 pH 3.0) and buffer B (30% acetonitrile, 5 mM NaH2PO4 pH 3.0, 500 mM CH3COONH4). The 12 steps (low to high salt) contained the following proportions of buffer B: 0%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, 50% and 100%. Each eluted fraction was dried and processed for the second dimension.

For reversed-phase analysis, an in-house C-18 reversed-phase pre-column and analytical column were used.21 Individual fractions from the SCX column were reconstituted in 0.1% acetic acid/water and loaded onto the reverse phase pre-column. The peptides were eluted using a 0–70% acetonitrile gradient over a period of 30 min. and separated on the analytical column with integrated 5 µm electrospray tip. The analytical column was connected on-line with a Thermo Finnigan hybrid ion trap Fourier transform (LTQ-FT) high resolution mass spectrometer, and tandem MS/MS spectra were acquired in real time. All the steps of reversed-phase analysis were performed in an automated fashion.21

MS/MS spectra were searched with the SEQUEST algorithm (version 27, revision 12) and assigned to peptide sequences from the NCBI non-redundant protein database sliced in Bioworks 3.1 for human proteins. Search parameters designated variable modifications of +79.9663 Da on Ser, Thr and Tyr for phosphorylation. Database identified peptides were filtered with Xcorr versus charge state. Only those peptides with a precursor mass error less than 20 ppm and Xcorr ≥ 1.5 (+1), 2 (+2) or 2.5 (≥ +3) were retained for further analysis. Peptides were quantified using inhouse developed software based on the ICIS algorithm within the Xcalibur XDK provided by ThermoFisher.

In label-free experiments peptides identified in various SCX fractions of one nuclear extract were combined into a single list. The lists of unique peptides for TAPMyc (sample) and HAMyc (control) extracts were compared to one another to compute the fold-enrichment of peptides in one sample versus the other. A peptide was considered to be enriched in the sample if its peak area was ≥ 2 in sample relative to control, and enriched in the control if its peak area was ≥ 2 in control relative to sample. Peptides with enrichments less than two-fold in either direction were not used for further analysis. A given protein was considered to be specifically enriched in the sample if greater than 50% of its detected peptides were enriched in sample versus control. Results from four individual biological replicates were combined to identify the proteins that were enriched in at least three of the four replicates.

Similar to the label-free experiments, in SILAC experiments only peptides assigned by SEQUEST with a precursor mass error of 20 ppm or less were considered. Additional variable modifications of +6.0201 Da on Lys and Arg were specified for the SILAC samples. A cut-off of 2% false discovery rate (FDR) estimated by decoy database search22 was also applied by constraining the logistic spectral score23 for the dataset. The ratio of selected ion chromatogram peak areas for sample versus control peptide pairs, of a given sequence and charge, were used to compute a SILAC peak area ratio. Peptides with a SILAC peak area ratio (sample/control) > 1.3 were considered enriched in the sample, and those with peak area ratio (control/sample) > 1.3 were considered enriched in the control. All peptides with enrichments less than 1.3-fold in either direction were discarded. Peptides for which one of the selected ion chromatograms (heavy or light) was not discernable above background but the other was present with a signal-to-noise ratio of 1.3:1 were also considered enriched. As above, a given protein was considered to be enriched if > 50% of its detected peptides were enriched in sample versus control. Four biological replicates were performed and analyzed by this process to score the number of replicates in which a given protein was enriched in sample versus control.

Acknowledgements

This work was supported in part by NIH/NIGMS grant R01 GM040960 and NIH/NIA grant R37 AG016694 to J.M.S. A.R.S. was supported in part by the COBRE award from the NIH/NCRR P20 RR015578. The Genomics Core Facility in the Laboratories for Molecular Medicine at Brown University was supported in part by the COBRE award from the NIH/NCRR P20 RR015578. J.M.S. is a Senior Scholar of the Ellison Medical Foundation.

Footnotes

Supplementary Material

Supplementary Material:

References

1. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8:976–990. [PubMed]
2. Albihn A, Johnsen JI, Henriksson MA. MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res. 2010;107:163–224. [PubMed]
3. Dai MS, Jin Y, Gallegos JR, Lu H. Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia. 2006;8:630–644. [PMC free article] [PubMed]
4. Ponzielli R, Katz S, Barsyte-Lovejoy D, Penn LZ. Cancer therapeutics: Targeting the dark side of Myc. Eur J Cancer. 2005;41:2485–2501. [PubMed]
5. Cole MD, Cowling VH. Transcription-independent functions of MYC: Regulation of translation and DNA replication. Nat Rev Mol Cell Biol. 2008;9:810–815. [PubMed]
6. Cowling VH, Cole MD. Mechanism of transcriptional activation by the Myc oncoproteins. Semin Cancer Biol. 2006;16:242–252. [PubMed]
7. Kleine-Kohlbrecher D, Adhikary S, Eilers M. Mechanisms of transcriptional repression by Myc. Curr Top Microbiol Immunol. 2006;302:51–62. [PubMed]
8. Mathivanan S, Periaswamy B, Gandhi TK, Kandasamy K, Suresh S, Mohmood R, et al. An evaluation of human protein-protein interaction data in the public domain. BMC Bioinform. 2006;7:19. [PMC free article] [PubMed]
9. Koch HB, Zhang R, Verdoodt B, Bailey A, Zhang CD, Yates JR, 3rd, et al. Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach. Cell Cycle. 2007;6:205–217. [PubMed]
10. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligandbinding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 1995;23:1686–1690. [PMC free article] [PubMed]
11. Wei W, Jobling WA, Chen W, Hahn WC, Sedivy JM. Abolition of cyclin-dependent kinase inhibitor p16Ink4a and p21Cip1/Waf1 functions permits Ras-induced anchorage-independent growth in telomerase-immortalized human fibroblasts. Mol Cell Biol. 2003;23:2859–2870. [PMC free article] [PubMed]
12. Rigaut G, Shevchenko A, Rutz B, Wilm M, Mann M, Seraphin B. A generic protein purification method for protein complex characterization and proteome exploration. Nat Biotechnol. 1999;17:1030–1032. [PubMed]
13. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science. 1997;277:831–834. [PubMed]
14. Bazarov AV, Adachi S, Li SF, Mateyak MK, Wei S, Sedivy JM. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation. Cancer Res. 2001;61:1178–1186. [PubMed]
15. Prouty SM, Hanson KD, Boyle AL, Brown JR, Shichiri M, Follansbee MR, et al. A cell culture model system for genetic analyses of the cell cycle by targeted homologous recombination. Oncogene. 1993;8:899–907. [PubMed]
16. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 1997;8:1039–1048. [PubMed]
17. Evan GI, Hancock DC. Studies on the interaction of the human c-myc protein with cell nuclei: p62c-myc as a member of a discrete subset of nuclear proteins. Cell. 1985;43:253–261. [PubMed]
18. Dignam JD, Martin PL, Shastry BS, Roeder RG. Eukaryotic gene transcription with purified components. Meth Enzymol. 1983;101:582–598. [PubMed]
19. Harlow E, Lane D. Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press; 1988.
20. Washburn MP, Wolters D, Yates JR., 3rd Large-scale analysis of the yeast proteome by multidimensional protein identification technology. Nat Biotechnol. 2001;19:242–247. [PubMed]
21. Ficarro SB, Salomon AR, Brill LM, Mason DE, Stettler-Gill M, Brock A, et al. Automated immobilized metal affinity chromatography/nano-liquid chromatography/electrospray ionization mass spectrometry platform for profiling protein phosphorylation sites. Rapid Commun Mass Spectrom. 2005;19:57–71. [PubMed]
22. Elias JE, Gygi SP. Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry. Nat Methods. 2007;4:207–214. [PubMed]
23. Yu K, Sabelli A, DeKeukelaere L, Park R, Sindi S, Gatsonis CA, et al. Integrated platform for manual and high-throughput statistical validation of tandem mass spectra. Proteomics. 2009;9:3115–3125. [PMC free article] [PubMed]
24. Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 1999;19:4672–4683. [PMC free article] [PubMed]
25. Schorl C, Sedivy JM. Loss of protooncogene c-Myc function impedes G1 phase progression both before and after the restriction point. Mol Biol Cell. 2003;14:823–835. [PMC free article] [PubMed]
26. Borg JP, Marchetto S, Le Bivic A, Ollendorff V, Jaulin-Bastard F, Saito H, et al. ERBIN: A basolateral PDZ protein that interacts with the mammalian ERBB2/HER2 receptor. Nat Cell Biol. 2000;2:407–414. [PubMed]
27. Dai P, Xiong WC, Mei L. Erbin inhibits RAF activation by disrupting the sur-8-Ras-Raf complex. J Biol Chem. 2006;281:927–933. [PubMed]
28. Ress A, Moelling K. Interaction partners of the PDZ domain of erbin. Protein Pept Lett. 2006;13:877–881. [PubMed]
29. Deliot N, Chavent M, Nourry C, Lecine P, Arnaud C, Hermant A, et al. Biochemical studies and molecular dynamics simulations of Smad3-Erbin interaction identify a non-classical Erbin PDZ binding. Biochem Biophys Res Commun. 2009;378:360–365. [PubMed]
30. Dai F, Chang C, Lin X, Dai P, Mei L, Feng XH. Erbin inhibits transforming growth factor beta signaling through a novel Smad interacting domain. Mol Cell Biol. 2007;27:6183–6194. [PMC free article] [PubMed]
31. Izumi Y, Hirai S, Tamai Y, Fujise-Matsuoka A, Nishimura Y, Ohno S. A protein kinase Cdelta-binding protein SRBC whose expression is induced by serum starvation. J Biol Chem. 1997;272:7381–7389. [PubMed]
32. Tong SY, Ki KD, Lee JM, Kang MJ, Ha TK, Chung SI, et al. Frequent inactivation of hSRBC in ovarian cancers by promoter CpG island hypermethylation. Acta Obstet Gynecol Scand. 2010;89:629–635. [PubMed]
33. Davidsson J, Lilljebjorn H, Andersson A, Veerla S, Heldrup J, Behrendtz M, et al. The DNA methylome of pediatric acute lymphoblastic leukemia. Hum Mol Genet. 2009;18:4054–4065. [PubMed]
34. Lee JH, Byun DS, Lee MG, Ryu BK, Kang MJ, Chae KS, et al. Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses. Int J Cancer. 2008;122:1573–1584. [PubMed]
35. Zochbauer-Muller S, Fong KM, Geradts J, Xu X, Seidl S, End-Pfutzenreuter A, et al. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Oncogene. 2005;24:6249–6255. [PubMed]
36. Xu XL, Wu LC, Du F, Davis A, Peyton M, Tomizawa Y, et al. Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res. 2001;61:7943–7949. [PubMed]
37. McMahon KA, Zajicek H, Li WP, Peyton MJ, Minna JD, Hernandez VJ, et al. SRBC/cavin-3 is a caveolin adapter protein that regulates caveolae function. EMBO J. 2009;28:1001–1015. [PubMed]
38. Bartholomew JN, Volonte D, Galbiati F. Caveolin-1 regulates the antagonistic pleiotropic properties of cellular senescence through a novel Mdm2/p53-mediated pathway. Cancer Res. 2009;69:2878–2886. [PMC free article] [PubMed]
39. Park J, Wood MA, Cole MD. BAF53 forms distinct nuclear complexes and functions as a critical c-Myc-interacting nuclear cofactor for oncogenic transformation. Mol Cell Biol. 2002;22:1307–1316. [PMC free article] [PubMed]
40. Andres V, Gonzalez JM. Role of A-type lamins in signaling, transcription, and chromatin organization. J Cell Biol. 2009;187:945–957. [PMC free article] [PubMed]
41. Conacci-Sorrell M, Ngouenet C, Eisenman RN. Mycnick: A cytoplasmic cleavage product of Myc that promotes alpha-tubulin acetylation and cell differentiation. Cell. 2010;142:480–493. [PMC free article] [PubMed]
42. Faiola F, Liu X, Lo S, Pan S, Zhang K, Lymar E, et al. Dual regulation of c-Myc by p300 via acetylationdependent control of Myc protein turnover and coactivation of Myc-induced transcription. Mol Cell Biol. 2005;25:10220–10234. [PMC free article] [PubMed]
43. Vervoorts J, Luscher-Firzlaff JM, Rottmann S, Lilischkis R, Walsemann G, Dohmann K, et al. Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP. EMBO Rep. 2003;4:484–490. [PubMed]
44. Beissbarth T, Speed TP. GOstat: Find statistically over-represented Gene Ontologies within a group of genes. Bioinformatics. 2004;20:1464–1465. [PubMed]
45. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57. [PubMed]
46. Nagy Z, Tora L. Distinct GCN5/PCAF-containing complexes function as co-activators and are involved in transcription factor and global histone acetylation. Oncogene. 2007;26:5341–5357. [PubMed]

Articles from Cell Cycle are provided here courtesy of Landes Bioscience